Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1949 1
1954 1
1956 2
1957 1
1958 1
1959 2
1962 2
1963 5
1964 8
1965 1
1971 1
1972 2
1973 14
1974 18
1975 25
1976 32
1977 14
1978 14
1979 20
1980 26
1981 24
1982 17
1983 12
1984 8
1985 11
1986 13
1987 17
1988 20
1989 21
1990 24
1991 50
1992 47
1993 64
1994 79
1995 65
1996 58
1997 62
1998 53
1999 70
2000 71
2001 100
2002 76
2003 83
2004 94
2005 144
2006 198
2007 262
2008 322
2009 447
2010 573
2011 593
2012 708
2013 779
2014 793
2015 832
2016 732
2017 754
2018 476
2019 433
2020 500
2021 586
2022 379
2023 193
2024 248

Search Results

9,928 results

Results by year

Filters applied: . Clear all
Page 1
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF; QuANTUM-First Study Group. Erba HP, et al. Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25. Lancet. 2023. PMID: 37116523 Clinical Trial.
Thyroid Cancer: A Review.
Boucai L, Zafereo M, Cabanillas ME. Boucai L, et al. JAMA. 2024 Feb 6;331(5):425-435. doi: 10.1001/jama.2023.26348. JAMA. 2024. PMID: 38319329 Review.
Resistance of Lenvatinib in Hepatocellular Carcinoma.
Guo J, Zhao J, Xu Q, Huang D. Guo J, et al. Curr Cancer Drug Targets. 2022;22(11):865-878. doi: 10.2174/1568009622666220428111327. Curr Cancer Drug Targets. 2022. PMID: 36267045 Review.
Lenvatinib-Associated Erythrocytosis.
Lakra R, Grewal US, Beedupalli K. Lakra R, et al. Am J Ther. 2024 Mar-Apr 01;31(2):e201-e203. doi: 10.1097/MJT.0000000000001606. Epub 2023 Mar 7. Am J Ther. 2024. PMID: 36989234 No abstract available.
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, Ye H, Wang Z, Chen S, Wang Y, Li X, Wang F, Cao J, Tian L, Zhao X, Chen M, Wang H, Cai S, Hu M, Bai Y, Lu S. Zhang W, et al. J Immunother Cancer. 2023 Sep;11(9):e007366. doi: 10.1136/jitc-2023-007366. J Immunother Cancer. 2023. PMID: 37730273 Free PMC article. Clinical Trial.
9,928 results